Laos Lucius Edition Ensi Dipine

Enasidenib is an oral targeted inhibitor used to treat a specific type of leukemia: newly diagnosed, refractory or relapsed acute myeloid leukemia (AML). It acts as an IDH2 (isocitrate dehydrogenase 2) inhibitor in AML patients with IDH2 mutations.

Ensidipine is currently not approved for sale in the domestic market, so domestic patients are faced with the dilemma of being unable to purchase it directly in the country. In order to obtain the medicines they need, they have to resort to purchasing them overseas. In the overseas drug market, generic drugs have become the first choice for patients because of their relatively affordable prices, especially the generic versions from Lucius Pharmaceuticals in Laos and Zisika Pharmaceuticals in Bangladesh. The price range of these drugs is roughly between 2,000 and 4,000 yuan, and it is worth noting that these generic drugs are highly consistent with the original drugs in terms of drug ingredients.

IDH2mutations are a common genetic variation in AML and occur in approximately 10% to 20% of AML patients. This mutation causes an abnormal increase in IDH2enzyme activity and produces large amounts of 2-hydroxyvaleric acid (2-HG), thus interfering with the normal differentiation and proliferation of cells. Ensidipine restores normal cell differentiation and proliferation by inhibiting this abnormal IDH2 enzyme activity and reducing 2-HG levels.

Ensidipine is an oral medication taken once daily. Before initiating treatment, a detailed clinical evaluation of the patient is required and assurance is required that the patient has IDH2mutated AML. During treatment, doctors usually adjust the dosage based on the patient's clinical response and tolerance.

Clinical trials show ensidipine is effective in treatingIDH2demonstrated significant antitumor activity in patients with mutated AML and produced durable clinical responses in some patients. It provides a new treatment option for patients who have previously received other treatments without efficacy, and improves patient prognosis to a certain extent.

However, ensidipine may also cause some adverse reactions, such as nausea, vomiting, fatigue, headache, etc. During the treatment process, the patient's condition needs to be closely monitored and corresponding treatment measures taken as needed.